Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”

Julia Clabbers; Celeste Boesjes; Michel van Geel; Marjolein de Bruin-Weller; Antoni Gostynski

doi:10.1016/j.jaad.2025.06.083

Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”

Julia Clabbers
, Celeste Boesjes
, Michel van Geel
, Marjolein de Bruin-Weller
, Antoni Gostynski^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	e43-e44
Journal	Journal of the American Academy of Dermatology
Volume	94
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2025.06.083
Publication status	Published - Jan 2026

Keywords

atopic dermatitis
biologics
dupilumab
filaggrin
skin barrier

Access to Document

10.1016/j.jaad.2025.06.083

PIIS0190962225027033Final published version, 79.2 KBLicence: Taverne

Cite this

Clabbers, J., Boesjes, C., van Geel, M., de Bruin-Weller, M., & Gostynski, A. (2026). Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”. Journal of the American Academy of Dermatology, 94(1), e43-e44. https://doi.org/10.1016/j.jaad.2025.06.083

Clabbers, Julia ; Boesjes, Celeste ; van Geel, Michel et al. / Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype : Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”. In: Journal of the American Academy of Dermatology. 2026 ; Vol. 94, No. 1. pp. e43-e44.

@article{fdcd0e7362434107a617130acd1e65f2,

title = "Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”",

keywords = "atopic dermatitis, biologics, dupilumab, filaggrin, skin barrier",

author = "Julia Clabbers and Celeste Boesjes and \{van Geel\}, Michel and \{de Bruin-Weller\}, Marjolein and Antoni Gostynski",

year = "2026",

month = jan,

doi = "10.1016/j.jaad.2025.06.083",

language = "English",

volume = "94",

pages = "e43--e44",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier",

number = "1",

}

Clabbers, J, Boesjes, C, van Geel, M, de Bruin-Weller, M & Gostynski, A 2026, 'Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”', Journal of the American Academy of Dermatology, vol. 94, no. 1, pp. e43-e44. https://doi.org/10.1016/j.jaad.2025.06.083

Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”. / Clabbers, Julia; Boesjes, Celeste; van Geel, Michel et al.
In: Journal of the American Academy of Dermatology, Vol. 94, No. 1, 01.2026, p. e43-e44.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype

T2 - Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”

AU - Clabbers, Julia

AU - Boesjes, Celeste

AU - van Geel, Michel

AU - de Bruin-Weller, Marjolein

AU - Gostynski, Antoni

PY - 2026/1

Y1 - 2026/1

KW - atopic dermatitis

KW - biologics

KW - dupilumab

KW - filaggrin

KW - skin barrier

UR - https://www.scopus.com/pages/publications/105024435319

U2 - 10.1016/j.jaad.2025.06.083

DO - 10.1016/j.jaad.2025.06.083

M3 - Letter

C2 - 40886833

AN - SCOPUS:105024435319

SN - 0190-9622

VL - 94

SP - e43-e44

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

Clabbers J, Boesjes C, van Geel M, de Bruin-Weller M, Gostynski A. Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”. Journal of the American Academy of Dermatology. 2026 Jan;94(1):e43-e44. doi: 10.1016/j.jaad.2025.06.083

Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”

Keywords

Access to Document

Other files and links

Cite this